Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis (DUET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01613118
Recruitment Status : Active, not recruiting
First Posted : June 6, 2012
Last Update Posted : March 20, 2018
Information provided by (Responsible Party):
Retrophin, Inc.

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Primary Completion Date : June 2016
  Estimated Study Completion Date : August 2021